Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Clinical Trials Clinical Trials Companies

GW Pharma High On Epilepsy Results, Plans 2017 NDA

Executive Summary

The biotech announces another set of positive anti-seizure results for its marijuana-derived product.

You may also be interested in...



Deal Watch: DelMar Takes On Unmet Need In Brain Cancer With Accurexa

Getting ready to take VAL-083 into Phase III in recurrent glioblastoma, DelMar also is partnering with Accurexa to develop an implantable wafer therapeutic combining the drug with other brain cancer chemotherapies. GW Pharmaceuticals sees a surge in its share price as speculation mounts about a possible takeout.

GW Pharmaceuticals High On Epilepsy Data

IPO Update: Patheon Public Once Again, Audentes To Move Into The Clinic

Two companies in the biopharma space began trading publicly this week, one to pay off debt, the other to fund an early-stage pipeline.

Table

View full table

Topics

Related Companies

Tags:
Clinical Trials Clinical Trials Companies
Latest Headlines

Investors Go Berserk For Viking, Putting It Top Of Q1 Winners

Sanofi Skates To Where The Puck Is With Immunology

Pipeline Watch: Five Approvals And 23 Phase III Updates

Metsera Launches As New Obesity Contender Flush With $290m

See All
UsernamePublicRestriction

Register

SC065523

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By